BackSoaring Eagle Acquisition - Warrants (23/02/2026) Overview

Soaring Eagle Acquisition - Warrants (23/02/2026) EBIT

Soaring Eagle Acquisition - Warrants (23/02/2026)'s EBIT is $-210M, below the Healthcare sector average of $23B.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$45.75M
30.2% YoY

As of Jun 30, 2026

Annual EBIT (TTM)

-$207.14M
45.03% YoY

Trailing 12 months ending Jun 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Soaring Eagle Acquisition - Warrants (23/02/2026) (SRNGW) FAQ

The latest EBIT for SRNGW is $-210M as of June 2026. That compares with $-380M in the prior-year period — up 45.0% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Soaring Eagle Acquisition - Warrants (23/02/2026)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, SRNGW's EBIT moved from $-380M to $-210M — a 45.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Soaring Eagle Acquisition - Warrants (23/02/2026)'s operating scale or balance-sheet position.

Against Healthcare companies, SRNGW currently prints $-210M for EBIT, while the sector average sits near $23B. That is roughly 100.9% below the sector mean. Large gaps often invite a closer look at Soaring Eagle Acquisition - Warrants (23/02/2026)'s growth, margins, and balance sheet.

A EBIT figure of $-210M for SRNGW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting SRNGW's EBIT ($-210M), review year-over-year change from $-380M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.